If approved by the FDA, aducanumab will become the first drug to slow the progression of Alzheimer’s
Did you know there’s such a thing as a physical for your brain? Find out what it is and how it can help if you’re concerned about your memory and cognitive function…
Welcome to the blog of the Memory and Aging Program (MAP) at Butler Hospital. We are a world leader in Alzheimer’s research and a local Rhode Island partner in the fight against Alzheimer’s disease and dementia. To learn more about our research and how to get involved, visit butler.org/memory.
Heroes & Pioneers
Ray and Elaine Theriault have embarked on many journeys in their 50+ years together. Now they’re on a new quest: to help end Alzheimer’s.
Research & Program News
Drug Studied at Butler Hospital’s Memory and Aging Program May Become First New Treatment for Alzheimer’s in 16 Years
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
Did you know there's such a thing as a physical for your brain? Athene Lee, PhD, assistant professor in psychiatry and human behavior and researcher at the Memory and Aging Program at Butler Hospital, explains what it is and how it can help if you're concerned about...
Join the Alzheimer's Prevention Registry
If you’re aged 40 to 85 and are an individual with normal memory, some memory decline, or mild dementia, you can help in the development of breakthrough tests and treatments for Alzheimer’s. Take just a few moments to enroll in our Alzheimer’s Prevention Registry, a tool that allows us to match up individuals interested in participating in research with studies for which they may qualify – either now or in the future.